sol-gel is a clinical-stage specialty pharmaceutical company focused on developing and commercializing topical dermatological drug products. our lead product candidates, vered for the treatment of papulopustular rosacea and twin and sirs-t for the treatment of acne vulgaris (“acne”) are based upon our proprietary microencapsulation delivery system. this technology consists of microcapsules made of silica. based on our pre-clinical and clinical data, this delivery system should enable us to develop and commercialize dermatological drug products that are more effective and/or have fewer side effects than currently marketed drugs. our silica-based delivery system improves the tolerability of topical dermatological drug products by entrapping drug substances in porous silica microcapsules. this creates a protective barrier between the drug substance and the skin and controls the release rate of the drug substance. our delivery system also enables to produce novel fixed-dose combinations th
Company profile
Ticker
SLGL
Exchange
Website
CEO
Alon Seri-Levy
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
SLGL stock data
Latest filings (excl ownership)
424B3
Prospectus supplement
4 Apr 24
EFFECT
Notice of effectiveness
2 Apr 24
6-K
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to
1 Apr 24
POS AM
Prospectus update (post-effective amendment)
20 Mar 24
20-F
2023 FY
Annual report (foreign)
13 Mar 24
6-K
Sol-Gel Reports Full-Year 2023 Financial Results and 2023 - Corporate Highlights and Recent Developments
13 Mar 24
6-K
Important Notice to Shareholders Who Are United States Persons
6 Mar 24
6-K
Current report (foreign)
29 Feb 24
6-K
Current report (foreign)
23 Jan 24
6-K
Current report (foreign)
17 Jan 24
Latest ownership filings
SC 13D/A
Arkin Moshe
8 Apr 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
Phoenix Holdings Ltd.
12 Feb 24
SC 13G
Migdal Insurance & Financial Holdings Ltd.
31 Jan 24
144
Notice of proposed sale of securities
28 Sep 23
144
Notice of proposed sale of securities
27 Sep 23
144
Notice of proposed sale of securities
26 Sep 23
144
Notice of proposed sale of securities
24 Jul 23
144
Notice of proposed sale of securities
27 Jun 23
144
Notice of proposed sale of securities
2 May 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
79.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 19 |
Opened positions | 2 |
Closed positions | 1 |
Increased positions | 2 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 9.30 bn |
Total shares | 22.11 mm |
Total puts | 0.00 |
Total calls | 500.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Arkin Moshe | 14.07 mm | $72.59 mm |
PXGPE Phoenix | 2.57 mm | $4.20 bn |
Armistice Capital | 2.14 mm | $3.48 bn |
Migdal Insurance & Financial | 1.23 mm | $2.01 mm |
Harel Insurance Investments & Financial Services | 920.33 k | $1.50 mm |
Kingdon Capital Management, L.L.C. | 766.86 k | $1.25 bn |
Yelin Lapidot Holdings Management | 229.18 k | $1.18 mm |
Raymond James Financial Services Advisors | 55.11 k | $89.83 mm |
Raymond James & Associates | 35.46 k | $57.80 mm |
MS Morgan Stanley | 29.24 k | $47.65 mm |